Resolution

of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive:
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a (SGB V)
Teclistamab (multiple myeloma, at least 3 prior therapies)

of 15 February 2024

At its session on 15 February 2024, the Federal Joint Committee (G-BA) resolved to amend the Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

I. Annex XII shall be amended in alphabetical order to include the active ingredient Teclistamab as follows:

Teclistamab

Resolution of: 15 February 2024
Entry into force on: 15 February 2024
Federal Gazette, BAnz AT DD. MM YYYY Bx

Therapeutic indication (according to the marketing authorisation of 23 August 2022):

Tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

Therapeutic indication of the resolution (resolution of 15 February 2024):

See therapeutic indication according to marketing authorisation.

1. Additional benefit of the medicinal product in relation to the appropriate comparator therapy

Adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy

Appropriate comparator therapy for teclistamab:

A patient-individual therapy under selection of:

- Bortezomib monotherapy
- Bortezomib + pegylated liposomal doxorubicin
- Bortezomib + dexamethasone
- Carfilzomib + lenalidomide and dexamethasone
- Carfilzomib + dexamethasone
- Daratumumab + lenalidomide + dexamethasone
- Daratumumab + bortezomib + dexamethasone
- Daratumumab monotherapy
- Daratumumab + pomalidomide + dexamethasone
- Elotuzumab + lenalidomide + dexamethasone
- Elotuzumab + pomalidomide + dexamethasone
- Isatuximab + pomalidomide + dexamethasone
- Ixazomib + lenalidomide + dexamethasone
- Lenalidomide + dexamethasone
- Panobinostat + bortezomib and dexamethasone
- Pomalidomide + bortezomib and dexamethasone
- Pomalidomide + dexamethasone
- Cyclophosphamide in combination with other antineoplastic medicinal products
- Melphalan as monotherapy or in combination with prednisolone or prednisone

- Doxorubicin as monotherapy or in combination with other antineoplastic medicinal products
- Vincristine in combination with other antineoplastic medicinal products
- Dexamethasone in combination with other antineoplastic medicinal products
- Prednisolone in combination with other antineoplastic medicinal products
- Prednisone in combination with other antineoplastic medicinal products
- Best supportive care

taking into account prior therapies as well as the extent and duration of the response.

Extent and probability of the additional benefit of teclistamab compared to the appropriate comparator therapy:

An additional benefit is not proven.

Study results according to endpoints:

Adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy

Summary of results for relevant clinical endpoints

No data are available to allow an assessment of the additional benefit.

Endpoint category	Direction of effect/ risk of bias	Summary
Mortality	n.a.	There are no assessable data.
Morbidity	n.a.	There are no assessable data.
Health-related quality of life	n.a.	There are no assessable data.
Side effects	n.a.	There are no assessable data.
Explanations: ↑: statistically significant and relevant positive effect with low/unclear reliability of data ↓: statistically significant and relevant negative effect with low/unclear reliability of data ↑↑: statistically significant and relevant positive effect with high reliability of data ↓↓: statistically significant and relevant negative effect with high reliability of data ↔: no statistically significant or relevant difference ∅: No data available. n.a.: not assessable		

2. Number of patients or demarcation of patient groups eligible for treatment

a) Adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy

approx. 1,210 – 1,310 patients

3. Requirements for a quality-assured application

The requirements in the product information are to be taken into account. The European Medicines Agency (EMA) provides the contents of the product information (summary of product characteristics, SmPC) for Tecvayli (active ingredient: teclistamab) at the following publicly accessible link (last access: 10 January 2024):

https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf

Treatment with teclistamab should only be initiated and monitored by specialists in internal medicine, haematology and, oncology experienced in the treatment of patients with multiple myeloma.

This medicinal product received a conditional marketing authorisation. This means that further evidence of the benefit of the medicinal product is anticipated. The European Medicines Agency will evaluate new information on this medicinal product at a minimum once per year and update the product information where necessary.

In accordance with the requirements of the European Medicines Agency (EMA) regarding additional risk minimisation measures, the pharmaceutical company must ensure that all patients and caregivers who are expected to come into contact with the use of teclistamab have access to a patient card or receive a patient card that informs and clarifies patients about the risks of CRS. The patient card also contains a warning for healthcare professionals that the patient is receiving teclistamab.

4. Treatment costs

Annual treatment costs:

The annual treatment costs shown refer to the first year of treatment.

Adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy

Designation of the therapy	Annual treatment costs/ patient
Medicinal product to be assessed:	
Teclistamab	
Teclistamab	€ 241,038.82
Additionally required SHI services	159.60 – 159.93
Appropriate comparator therapy	
Bortezomib monotherapy	
Bortezomib	€ 5,603.52
Bortezomib in combination with pegylated liposomal doxorubicin	
Bortezomib	€ 5,603.52
Doxorubicin (pegylated, liposomal)	€ 17,454.64
Total	€ 23,058.16
Bortezomib in combination with dexamethasone	
Bortezomib	€ 2,801.76 - € 5,603.52
Dexamethasone	€ 104.18 - € 168.97
Total	€ 2,905.94 - € 5,772.49
Carfilzomib in combination with lenalidomide and dexamethasone	
Carfilzomib	€ 80,017.58
Lenalidomide	€ 463.41
Dexamethasone	€ 193.47
Total	€ 80,674.46
Additionally required SHI services	€ 106.40
Carfilzomib in combination with dexamethasone	
Carfilzomib	€ 150,928.12
Dexamethasone	€ 243.11
Total	€ 151,171.23
Daratumumab in combination with lenalidomide and dexamethasone	
Daratumumab	€ 136,512.82
Lenalidomide	€ 463.41
Dexamethasone	€ 107.90

Designation of the therapy	Annual treatment costs/ patient
Total	€ 137,084.12
Additionally required SHI services	€ 346.75 - € 350.05
Daratumumab in combination with bortezomib and dexamethasone	
Daratumumab	€ 124,642.14
Bortezomib	€ 5,603.52
Dexamethasone	€ 147.30
Total	€ 130,392.96
Additionally required SHI services	€ 296.81 - € 299.82
Daratumumab in combination with pomalidomide and dexamethasone	
Daratumumab	€ 136,512.82
Pomalidomide	€ 111,053.02
Dexamethasone	€ 107.90
Total	€ 247,673.74
Additionally required SHI services	€ 346.75 - € 350.05
Daratumumab monotherapy	
Daratumumab	€ 136,512.82
Additionally required SHI services	€ 409.14 - € 669.20
Elotuzumab in combination with lenalidomide and dexamethasone	
Elotuzumab	€ 88,213.80
Lenalidomide	€ 463.41
Dexamethasone	€ 185.74
Total	€ 88,862.95
Additionally required SHI services	€ 340.08 - € 344.38
Elotuzumab + pomalidomide + dexamethasone	
Elotuzumab	€ 88,213.80
Pomalidomide	€ 111,053.02
Dexamethasone	€ 188.58
Total	€ 199,455.40
Additionally required SHI services	€ 254.39 - € 257.12
Isatuximab in combination with pomalidomide and dexamethasone	
Isatuximab	€ 69,231.68
Pomalidomide	€ 111,053.02
Dexamethasone	€ 104.18

Designation of the therapy	Annual treatment costs/ patient
Total	€ 180,388.88
Additionally required SHI services	€ 106.40
Ixazomib in combination with lenalidomide and dexamethasone	
Ixazomib	€ 78,848.90
Lenalidomide	€ 463.41
Dexamethasone	€ 193.47
Total	€ 79,505.78
Additionally required SHI services	€ 106.40
Lenalidomide in combination with dexamethasone	
Lenalidomide	€ 463.41
Dexamethasone	€ 312.53
Total	€ 775.94
Additionally required SHI services	€ 106.40
Panobinostat in combination with bortezomib and dexamethasone	
Panobinostat	€ 35,134.16 - € 70,268.32
Bortezomib	€ 5,603.52 - € 8,405.28
Dexamethasone	€ 168.97 - € 233.76
Total	€ 40,906.65 - € 78,907.36
Pomalidomide in combination with bortezomib and dexamethasone	
Pomalidomide	€ 99,093.46
Bortezomib	€ 8,895.59
Dexamethasone	€ 237.50
Total	€ 108,226.55
Additionally required SHI services	€ 106.40
Pomalidomide in combination with dexamethasone	
Pomalidomide	€ 111,053.02
Dexamethasone	€ 193.47
Total	€ 111,246.49
Additionally required SHI services	€ 106.40
Cyclophosphamide in combination with other antineoplastic medicinal products	
Cyclophosphamide	€ 206.30
Melphalan	€ 344.45
Carmustine	€ 38,015.54

Designation of the therapy	Annual treatment costs/ patient
Vincristine	€ 357.86
Prednisone	€ 133.34
Total	€ 39,057.49
Melphalan monotherapy	
Melphalan	€ 624.91
Melphalan in combination with prednisolone or prednisone	
Melphalan	€ 418.21 - € 624.91
Prednisolone	€ 62.71 - € 93.70
Total	€ 480.92 - € 718.61
Prednisone	€ 133.54 - € 199.54
Total	€ 551.75 - € 824.45
Doxorubicin	
Doxorubicin	€ 2,498.16 - € 3,747.24
Doxorubicin in combination with other antineoplastic medicinal products	
Incalculable.	
Vincristine in combination with other antineoplastic medicinal products	
Cyclophosphamide	€ 206.30
Melphalan	€ 344.45
Carmustine	€ 38,015.54
Vincristine	€ 357.86
Prednisone	€ 133.34
Total	€ 39,057.49
Dexamethasone in combination with other antineoplastic medicinal products [1]	
Prednisolone in combination with other antineoplastic medicinal products	

[1] The cost representation of the combination of dexamethasone with other antineoplastic medicinal products is already adequately illustrated by the following therapy options:

- Pomalidomide in combination with dexamethasone
- Pomalidomide in combination with bortezomib and dexamethasone
- Panobinostat in combination with bortezomib and dexamethasone
- Lenalidomide in combination with dexamethasone
- Ixazomib in combination with lenalidomide and dexamethasone
- Isatuximab in combination with pomalidomide and dexamethasone
- Elotuzumab + pomalidomide + dexamethasone
- Elotuzumab in combination with lenalidomide and dexamethasone
- Daratumumab in combination with bortezomib and dexamethasone
- Daratumumab in combination with lenalidomide and dexamethasone
- Carfilzomib in combination with dexamethasone
- Carfilzomib in combination with lenalidomide and dexamethasone
- Bortezomib in combination with dexamethasone

Designation of the therapy	Annual treatment costs/ patient
Cyclophosphamide	€ 206.30
Melphalan	€ 344.45
Carmustine	€ 38,015.54
Vincristine	€ 357.86
Prednisolone	€ 73.27
Total	€ 38,997.42
Prednisone in combination with other antineoplastic medicinal products	
Cyclophosphamide	€ 206.30
Melphalan	€ 344.45
Carmustine	€ 38,015.54
Vincristine	€ 357.86
Prednisone	€ 133.34
Total	€ 39,057.49
Best supportive care	
Best supportive care [2]	Different from patient to patient

Costs after deduction of statutory rebates (LAUER-TAXE®) as last revised: 15 January 2024)

Other SHI services:

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
Medicinal product to be assessed:					
Teclistamab					
Teclistamab	Surcharge for the preparation of a parenteral solution containing monoclonal antibodies	€ 100	Step-up: 3 days Maintenance: 38 days	41.0	€ 4,100
Appropriate comparator therapy					

2 When comparing teclistamab versus best supportive care, the costs of best supportive care must also be additionally considered for the medicinal product to be assessed.

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
Bortezomib monotherapy					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	4	32.0	€ 3,200
Bortezomib in combination with pegylated liposomal doxorubicin					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	4	32.0	€ 3,200
Doxorubicin (pegylated, liposomal)	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	Day 4 21-day cycle	8.0	€ 800
Bortezomib in combination with dexamethasone					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	4	16.0 – 32.0	€ 1,600 - € 3,200
Carfilzomib in combination with lenalidomide and dexamethasone					
Carfilzomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1st - 12th cycle: 6 From 13th cycle: 4	76.0	€ 7,600
Carfilzomib in combination with dexamethasone					
Carfilzomib	Surcharge for production of a parenteral	€ 100	6	78.0	€ 7,800

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
	preparation containing cytostatic agents				
Daratumumab in combination with bortezomib and dexamethasone					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	4	32.0	€ 3,200
Elotuzumab in combination with lenalidomide and dexamethasone					
Elotuzumab	Surcharge for the preparation of a parenteral solution containing monoclonal antibodies	€ 100	1st - 2nd cycle: 4 From 3rd cycle: 2	30.0	€ 3,000
Elotuzumab + pomalidomide + dexamethasone					
Elotuzumab	Surcharge for the preparation of a parenteral solution containing monoclonal antibodies	€ 100	1st - 2nd cycle: 4 From 3rd cycle: 1	19.0	€ 1,900
Isatuximab in combination with pomalidomide and dexamethasone					
Isatuximab	Surcharge for the preparation of a parenteral solution containing monoclonal antibodies	€ 100	1st cycle: 4 From 2nd cycle: 2	28.0	€ 2,800
Panobinostat in combination with bortezomib and dexamethasone					
Bortezomib	Surcharge for production of a parenteral	€ 100	1st - 8th cycle: 4	32.0 – 48.0	€ 3,200 – € 4,800

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
	preparation containing cytostatic agents		9th - 16th cycle: 2		
Pomalidomide in combination with bortezomib and dexamethasone					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1st - 8th cycle: 4 From 9th cycle: 2	50.8	€ 5,080
Cyclophosphamide in combination with other antineoplastic medicinal products					
Cyclophosphamide	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040
Carmustine	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040
Vincristine	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040
Melphalan monotherapy					
Melphalan	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	13.0	€ 1,300
Melphalan in combination with prednisolone or prednisone					

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
Melphalan	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	8.7 – 13.0	€ 870 - € 1,300
Doxorubicin monotherapy					
Doxorubicin	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	6.0 – 9.0	€ 600 - € 900
Vincristine in combination with other antineoplastic medicinal products					
Cyclophosphamide	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040
Carmustine	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040
Vincristine	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040
Prednisolone in combination with other antineoplastic medicinal products					
Cyclophosphamide	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
Carmustine	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040
Vincristine	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040
Prednisone in combination with other antineoplastic medicinal products					
Cyclophosphamide	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040
Carmustine	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040
Vincristine	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	10.4	€ 1,040

5. Designation of medicinal products with new active ingredients according to Section 35a, paragraph 3, sentence 4 SGB V that can be used in a combination therapy with the assessed medicinal product

In the context of the designation of medicinal products with new active ingredients pursuant to Section 35a, paragraph 3, sentence 4 SGB V, the following findings are made:

Adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy

- No designation of medicinal products with new active ingredients that can be used in combination therapy pursuant to Section 35a, paragraph 3, sentence 4 SGB V, as the active ingredient to be assessed is an active ingredient authorised in monotherapy.

The designation of combinations exclusively serves the implementation of the combination discount according to Section 130e SGB V between health insurance funds and pharmaceutical companies. The findings made neither restrict the scope of treatment required to fulfil the medical treatment mandate, nor do they make statements about expediency or economic feasibility.

II. Entry into force

1. **The resolution will enter into force on the day of its publication on the website of the G-BA on 15 February 2024.**

2. **The period of validity of the resolution is limited to 1 January 2027.**

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de**.**

Berlin, 15 February 2024

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken